Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.
Three chimpanzees immunized with recombinant gp120 from human immunodeficiency virus type 1 (HIV-1) strain MN and 1 control animal were challenged intravenously with a primary isolate of HIV-1SF2. Viral infection was detected in the control animal by viral culture, polymerase chain reaction, and multiple serologic assays beginning 2 weeks after infection. Markers of HIV-1 infection were not detected in any of the gp120-vaccinated animals during 12 months of follow-up. Antisera from the gp120-immunized chimpanzees were unable to neutralize the challenge virus cultured in peripheral blood mononuclear cells (PBMC). These studies demonstrate that immunization with recombinant gp120 derived from a T cell-adapted isolate prevented infection by a heterologous primary isolate of HIV-1. The results suggest that in vitro virus neutralization assays utilizing primary isolates cultured in PBMC may be imperfect indicators of protection in vivo.
Department of Immunology, Genentech, Inc., South San Francisco, California 94080, USA.
P W
PW
Berman
K K
KK
Murthy
T
T
Wrin
J C
JC
Vennari
E K
EK
Cobb
D J
DJ
Eastman
M
M
Champe
G R
GR
Nakamura
D
D
Davison
M F
MF
Powell
J
J
Bussiere
D P
DP
Francis
T
T
Matthews
T J
TJ
Gregory
J F
JF
Obijeski
D016915:AIDS Vaccines; D000818:Animals; D001483:Base Sequence; D017931:DNA Primers / Q000737:chemistry; D004279:DNA, Viral / Q000032:analysis; D015483:HIV Antibodies / Q000032:analysis; D015488:HIV Antigens / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D007114:Immunization; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D002679:Pan troglodytes; D013601:T-Lymphocytes / Q000821:virology; D014614:Vaccines, Synthetic; D014776:Virus Cultivation
D016915:AIDS Vaccines; D017931:DNA Primers; D004279:DNA, Viral; D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; D014614:Vaccines, Synthetic